Histone Deacetylase 10 Inhibitors Suppress Progression of Endometriosis via Activation of Interferon Regulatory Factor 6 and Dachshund Homolog 1

We assessed the effects of HDAC10Is, tucidinostat and TH34, on the proliferation and the cell cycle in human endometriotic cyst stromal cells (ECSCs). Target genes of HDAC10 were identified by RNA sequencing. We assessed the expression of dachshund homolog 1 (DACH1) and interferon regulatory factor 6 (IRF6) mRNA in ECSCs and normal endometrial stromal cells. The functions of DACH1 and IRF6 were confirmed by compulsory expression of these genes in ECSCs using lentivirus. Effects of tucidinostat and TH34 on the promoter acetylation of the DACH1 and IRF6 genes in ECSCs were assessed by chromatin immunoprecipitation assays.

Both HDAC10Is had an inhibitory effect on the proliferation of ECSCs and caused them to enter cell cycle arrest at G0/G1. DACH1 and IRF6 were identified as the target genes of HDAC10. HDAC10Is caused acetylated histones to accumulate in the promoters of the genes encoding DACH1 and IRF6 in ECSCs.

These findings indicate that HDAC10 is a factor which contributes to endometriosis pathogenesis by inhibiting DACH1 and IRF6 expression, and that HDAC10Is are therefore promising agents for endometriosis treatment. Disclosure An earlier version of this article was presented at the Annual Meeting of Japan Endometriosis Society, which was held in Tokyo, Japan, on 20–21 January 2024, the Annual Meeting of Japan Society of Obstetrics and Gynecology, which was held in Kanagawa, Japan, on 19–21 April 2024, the Annual Meeting of Japan Endometriosis Society, which was held in Shiga, Japan, on 25–26 January 2025, and the 16th World Congress on Endometriosis 2025, which was held in Sidney, Australia, on 21–24 May 2025. Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement RNA sequencing data are available at Gene Expression Omnibus via the National Center for Biotechnology Information under Accession No. GSE309027 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309027).

- 1L. C. Giudice, “Clinical practice. Endometriosis,” New England Journal of Medicine 362 (2010): 2389–2398. - 2K. T. Zondervan, C. M. Becker, and S. A. Missmer, “Endometriosis,” New England Journal of Medicine 382 (2020): 1244–1256. - 3 Practice Committee of the American Society for Reproductive Medicine, “Endometriosis and Infertility,” Fertility and Sterility 81 (2004): 1441–1446. - 4K. Nasu, A. Tsuno, A. Yuge, Y. Kawano, and H. Narahara, “Combined Oral Contraceptives for the Medical Treatment of Endometriosis-Associated Pain,” Recent Advances in Endocrinology and Metabolism 1 (2009): 1–14. - 5B. A. Lessey, “Medical Management of Endometriosis and Infertility,” Fertility and Sterility 73 (2000): 1089–1096. - 6S. E. Bulun, Z. Lin, G. Imir, et al., “Regulation of Aromatase Expression in Estrogen-Responsive Breast and Uterine Disease: From Bench to Treatment,” Pharmacological Reviews 57 (2005): 359–383. - 7A. Bergqvist, “A Comparative Study of the Acceptability and Effect of Goserelin and Nafarelin on Endometriosis,” Gynecological Endocrinology 14 (2000): 425–432. - 8A. D. Goldberg, C. D. Allis, and E. Bernstein, “Epigenetics: A Landscape Takes Shape,” Cell 128 (2007): 635–638. - 9E. Seto and M. Yoshida, “Erasers of Histone Acetylation: The Histone Deacetylase Enzymes,” Cold Spring Harbor Perspectives in Biology 6 (2014): a018713. - 10K.-Y. Hsiao, M.-H. Wu, and S.-J. Tsai, “Epigenetic Regulation of the Pathological Process in Endometriosis,” Reproductive Medicine and Biology 16 (2017): 314–319. - 11R. M. Marquardt, D. N. Tran, B. A. Lessey, M. S. Rahman, and J. W. Jeong, “Epigenetic Dysregulation in Endometriosis: Implications for Pathophysiology and Therapeutics,” Endocrine Reviews 44 (2023): 1074–1095. - 12I. Psilopatis, K. Vrettou, F. N. Fleckenstein, and S. Theocharis, “The Impact of Histone Modifications in Endometriosis Highlights New Therapeutic Opportunities,” Cells 12 (2023): 1227. - 13S. W. Guo, “Epigenetics of Endometriosis,” Molecular Human Reproduction 15 (2009): 587–607. - 14K. Nasu, Y. Kawano, K. Kai, et al., “Aberrant Histone Modification in Endometriosis,” Frontiers in Bioscience 19 (2014): 1202–1214. - 15Y. Aoyagi, K. Nasu, K. Kai, et al., “Decidualization Differentially Regulates microRNA Expression in Eutopic and Ectopic Endometrial Stromal Cells,” Reproductive Sciences 24 (2017): 445–455. - 16M. Nishida, K. Nasu, J. Fukuda, Y. Kawano, H. Narahara, and I. Miyakawa, “Down Regulation of Interleukin-1 Receptor Expression Causes the Dysregulated Expression of CXC Chemokines in Endometriotic Stromal Cells: A Possible Mechanism for the Altered Immunological Functions in Endometriosis,” Journal of Clinical Endocrinology and Metabolism 89 (2004): 5094–5100. - 17W. Abe, K. Nasu, C. Nakada, Y. Kawano, M. Moriyama, and H. Narahara, “miR-196b Targets c-Myc and Bcl-2 Expression, Inhibits Proliferation and Induces Apoptosis in Endometriotic Stromal Cells,” Human Reproduction 28 (2013): 750–761. - 18Y. Kawano, K. Nasu, H. Li, et al., “Application of the Histone Deacetylase Inhibitors for the Treatment of Endometriosis: Histone Modifications as Pathogenesis and Novel Therapeutic Target,” Human Reproduction 26 (2011): 2486–2498. - 19P. J. Thul and C. Lindskog, “The Human Protein Atlas: A Spatial Map of the Human Proteome,” Protein Science 27 (2018): 233–244. - 20R. Zhu, K. Nasu, N. Hijiya, et al., “Hsa-miR-199a-3p Inhibits Motility, Invasiveness, and Contractility of Ovarian Endometriotic Stromal Cells,” Reproductive Sciences 28 (2021): 3498–3507. - 21Y. Kawano, K. Nasu, N. Hijiya, et al., “CCAAT/Enhancer-Binding Protein α Is Epigenetically Silenced by Histone Deacetylation in Endometriosis and Promotes the Pathogenesis of Endometriosis,” Journal of Clinical Endocrinology and Metabolism 98 (2013): E1474–E1482. - 22L. Sun, Q. He, C. Tsai, et al., “HDAC Inhibitors Suppressed Small Cell Lung Cancer Cell Growth and Enhanced the Suppressive Effects of Receptor-Targeting Cytotoxins via Upregulating Somatostatin Receptor II,” American Journal of Translational Research 10 (2018): 545–553. - 23C. J. Auernhammer, K. Zitzmann, S. Lindner, et al., “Upregulation of SSTR2 Expression and Radioligand Binding of [18F]SiTATE in Neuroendocrine Tumour Cells With Combined Inhibition of Class I HDACs and LSD1,” Neuroendocrinology 115 (2025): 618–631. - 24S. E. Lynch, C. I. Crawford, H. A. Houson, et al., “Characterizing SSTR2 Expression and Modulation for Targeted Imaging and Therapy in Preclinical Models of Triple-Negative Breast Cancer,” Scientific Reports 15 (2025): 9988. - 25M. Colón-Díaz, P. Báez-Vega, M. García, et al., “HDAC1 and HDAC2 Are Differentially Expressed in Endometriosis,” Reproductive Sciences 19 (2012): 483–492. - 26E. P. Samartzis, A. Noske, N. Samartzis, D. Fink, and P. Imesch, “The Expression of Histone Deacetylase 1, but Not Other Class I Histone Deacetylases, Is Significantly Increased in Endometriosis,” Reproductive Sciences 20 (2013): 1416–1422. - 27Z. Zelenko, L. Aghajanova, J. C. Irwin, and L. C. Giudice, “Nuclear Receptor, Coregulator Signaling, and Chromatin Remodeling Pathways Suggest Involvement of the Epigenome in the Steroid Hormone Response of Endometrium and Abnormalities in Endometriosis,” Reproductive Sciences 19 (2012): 152–162. - 28H. Zheng, X. Liu, and S.-W. Guo, “Corroborating Evidence for Aberrant Expression of Histone Deacetylase 8 in Endometriosis,” Reproductive Medicine and Biology 22 (2023): e12527. - 29J. Zingg, D. R. Kalaitzopoulos, A. A. Karol, et al., “Expression Patterns of HDAC6 in Correlation to ARID1A Status in Different Subtypes of Endometriosis: A Retrospective Tissue Microarray Analysis,” European Journal of Obstetrics & Gynecology and Reproductive Biology 302 (2024): 73–80. - 30Y. Wu and S. W. Guo, “Histone Deacetylase Inhibitors Trichostatin A and Valproic Acid Induce Cell Cycle Arrest and p21 Expression in Immortalized Human Endometrial Stromal Cells,” European Journal of Obstetrics & Gynecology and Reproductive Biology 137 (2008): 198–203. - 31P. Imesch, D. Fink, and A. Fedier, “Romidepsin Reduces Histone Deacetylase Activity, Induces Acetylation of Histones, Inhibits Proliferation, and Activates Apoptosis in Immortalized Epithelial Endometriotic Cells,” Fertility and Sterility 94 (2010): 2838–2842. - 32I. Oehme, J. P. Linke, B. C. Böck, et al., “Histone Deacetylase 10 Promotes Autophagy-Mediated Cell Survival,” Proceedings of the National Academy of Sciences of the United States of America 110 (2013): E2592–E2601. - 33C. Song, S. Zhu, C. Wu, and J. Kang, “Histone Deacetylase (HDAC) 10 Suppresses Cervical Cancer Metastasis Through Inhibition of Matrix Metalloproteinase (MMP) 2 and 9 Expression,” Journal of Biological Chemistry 288 (2013): 28021–28033. - 34X. Liu, Y. Wang, R. Zhang, et al., “HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC,” Frontiers in Oncology 10 (2020): 485. - 35H. Guo, H. Ren, K. Han, et al., “Knockdown of HDAC10 Inhibits POLE2-Mediated DNA Damage Repair in NSCLC Cells by Increasing SP1 Acetylation Levels,” Pulmonary Pharmacology & Therapeutics 83 (2023): 102250. - 36H. Ling, Y. Li, C. Peng, S. Yang, and E. Seto, “HDAC10 Inhibition Represses Melanoma Cell Growth and BRAF Inhibitor Resistance via Upregulating SPARC Expression,” Nucleic Acids Research Cancer 6 (2024): zcae018. - 37L. Yang, Q. Wei, X. Chen, et al., “Identification of HDAC10 as a Candidate Oncogene in Clear Cell Renal Carcinoma That Facilitates Tumor Proliferation and Metastasis,” Diagnostic Pathology 19 (2024): 120. - 38H. H. Nie, X. Y. Yang, J. K. Zhou, et al., “Histone Deacetylases 10 as a Prognostic Biomarker Correlates With Tumor Microenvironment and Therapy Response in Colorectal Cancer,” World Journal of Gastroenterology 31 (2025): 108662. - 39L. Liu, B. Chen, S. Qin, et al., “A Novel Histone Deacetylase Inhibitor Chidamide Induces Apoptosis of Human Colon Cancer Cells,” Biochemical and Biophysical Research Communications 392 (2010): 190–195. - 40F. R. Kolbinger, E. Koeneke, J. Ridinger, et al., “The HDAC6/8/10 Inhibitor TH34 Induces DNA Damage-Mediated Cell Death in Human High-Grade Neuroblastoma Cell Lines,” Archives of Toxicology 92 (2018): 2649–2664. - 41R. R. Steimbach, C. J. Herbst-Gervasoni, S. Lechner, et al., “Aza-SAHA Derivatives Are Selective Histone Deacetylase 10 Chemical Probes That Inhibit Polyamine Deacetylation and Phenocopy HDAC10 Knockout,” Journal of the American Chemical Society 144 (2022): 18861–18875. - 42M. Morgen, R. R. Steimbach, M. Géraldy, et al., “Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors,” Chemistry & Medicinal Chemistry 15 (2020): 1163–1174. - 43J. Mao, S. Li, H. Zhao, et al., “Effects of Chidamide and Its Combination With Decitabine on Proliferation and Apoptosis of Leukemia Cell Lines,” American Journal of Translational Research 10 (2018): 2567–2578. - 44X. Jiang, L. Jiang, J. Cheng, et al., “Inhibition of EZH2 by Chidamide Exerts Antileukemia Activity and Increases Chemosensitivity Through Smo/Gli-1 Pathway in Acute Myeloid Leukemia,” Journal of Translational Medicine 19 (2021): 117. - 45Y. Shi, M. Dong, X. Hong, et al., “Results From a Multicenter, Open-Label, Pivotal Phase II Study of Chidamide in Relapsed or Refractory Peripheral T-Cell Lymphoma,” Annals of Oncology 26 (2015): 1766–1771. - 46F. Nan, Q. Lu, J. Zhou, et al., “Altered Expression of DACH1 and Cyclin D1 in Endometrial Cancer,” Cancer Biology & Therapy 8 (2009): 1534–1539. - 47K. Wu, A. Li, M. Rao, et al., “DACH1 Is a Cell Fate Determination Factor That Inhibits Cyclin D1 and Breast Tumor Growth,” Molecular and Cellular Biology 26 (2006): 7116–7129. - 48K. Wu, S. Katiyar, A. Witkiewicz, et al., “The Cell Fate Determination Factor Dachshund Inhibits Androgen Receptor Signaling and Prostate Cancer Cellular Growth,” Cancer Research 69 (2009): 3347–3355. - 49W. Yan, K. Wu, J. G. Herman, et al., “Epigenetic Regulation of DACH1, a Novel Wnt Signaling Component in Colorectal Cancer,” Epigenetics 8 (2013): 1373–1383. - 50Y. Liu, R. Zhou, X. Yuan, et al., “DACH1 Is a Novel Predictive and Prognostic Biomarker in Hepatocellular Carcinoma as a Negative Regulator of Wnt/β-Catenin Signaling,” Oncotarget 6 (2015): 8621–8634. - 51G. S. Dalgin, M. Drever, T. Williams, T. King, C. DeLisi, and L. S. Liou, “Identification of Novel Epigenetic Markers for Clear Cell Renal Cell Carcinoma,” Journal of Urology 180 (2008): 1126–1130. - 52J. Yu, P. Jiang, K. Zhao, Z. Chen, T. Zuo, and B. Chen, “Role of DACH1 on Proliferation, Invasion, and Apoptosis in Human Lung Adenocarcinoma Cells,” Current Molecular Medicine 21 (2021): 806–811. - 53K. Chen, K. Wu, X. Jiao, et al., “The Endogenous Cell-Fate Factor Dachshund Restrains Prostate Epithelial Cell Migration via Repression of Cytokine Secretion via a CXCL Signaling Module,” Cancer Research 75 (2015): 1992–2004. - 54F. Zhao, M. Wang, S. Li, et al., “DACH1 Inhibits SNAI1-Mediated Epithelial-Mesenchymal Transition and Represses Breast Carcinoma Metastasis,” Oncogene 4 (2015): e143. - 55Y. Liu, N. Han, S. Zhou, et al., “The DACH/EYA/SIX Gene Network and Its Role in Tumor Initiation and Progression,” International Journal of Cancer 138 (2016): 1067–1075. - 56T. Doke, S. Huang, C. Qiu, et al., “Transcriptome-Wide Association Analysis Identifies DACH1 as a Kidney Disease Risk Gene That Contributes to Fibrosis,” Journal of Clinical Investigation 131 (2021): e141801. - 57L. Ozcan, D. S. Ghorpade, Z. Zheng, et al., “Hepatocyte DACH1 Is Increased in Obesity via Nuclear Exclusion of HDAC4 and Promotes Hepatic Insulin Resistance,” Cell Reports 15 (2016): 2214–2225. - 58Y. A. Kousa and B. C. Schutte, “Toward an Orofacial Gene Regulatory Network,” Developmental Dynamics 245 (2016): 220–232. - 59R. J. Richardson, J. Dixon, S. Malhotra, et al., “Irf6 Is a Key Determinant of the Keratinocyte Proliferation-Differentiation Switch,” Nature Genetics 38 (2006): 1329–1334. - 60E. Girousi, L. Muerner, L. Parisi, et al., “Lack of IRF6 Disrupts Human Epithelial Homeostasis by Altering Colony Morphology, Migration Pattern, and Differentiation Potential of Keratinocytes,” Frontiers in Cell and Developmental Biology 9 (2021): 718066. - 61E. Botti, G. Spallone, F. Moretti, et al., “Developmental Factor IRF6 Exhibits Tumor Suppressor Activity in Squamous Cell Carcinomas,” Proceedings of the National Academy of Sciences of the United States of America 108 (2011): 13710–13715. - 62L. Parisi, C. Mockenhaupt, S. Rihs, F. Mansour, C. Katsaros, and M. Degen, “Consistent Downregulation of the Cleft Lip/Palate-Associated Genes IRF6 and GRHL3 in Carcinomas,” Frontiers in Oncology 12 (2022): 1023072. Article Metrics Total unique accesses to an article’s full text in HTML or PDF/ePDF format.More metric information Scite metrics Explore this article's citation statements on scite.ai Share QR Code Generating QR code QR code copied to clipboard! Something went wrong while generating your QR code. Please try again in a moment. If the issue persists, refresh the page or contact support. Export citation Unable to load citation data. Please try again in a moment. How to cite Elkins, L. J., & Spiegelman, M. (2021). pyUserCalc: A revised Jupyter notebook calculator for uranium-series disequilibria in basalts. Earth and Space Science, 8, e2020EA001619. https://doi.org/10.1029/2020EA001619 Download Citation If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click on download. This feature enables you to download the bibliographic information (also called citation data, header data, or metadata) for the articles on our site. Citation manager file format Use the dropdown list to choose how to format the bibliographic data you're harvesting. Several citation manager formats are available, including EndNote and BibTex. You can then copy the formatted citation (as displayed) or download it as file, to your device. If the RefWorks format is chosen, the 'Download' button will be replaced with an option to directly export to RefWorks